Skip to main content
Fig. 1 | Molecular Neurodegeneration

Fig. 1

From: A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer’s disease

Fig. 1

Redesigning of the anticonvulsant Zendra for treatment of AD and dementia. The redesigned small molecule, NMZ, should retain the reported neuroprotective properties, while additionally targeting synaptic dysfunction, the case for which in AD is persuasive [16]. NMZ was designed to restore synaptic function via NO/cGMP/CREB signaling, and to retain the beneficial actions of CMZ. The desired activity profile was observed in multiple animal models on treatment with NMZ. Table indicates a summary of performed assays in used mouse models

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326